BusinessTimes.top
BusinessTimes is for folks who likes to get updated before others about latest news of Stock Markets, Business News, Personal Funds, Currencies and Much More. If you have any kind of questions, please feel free to ask by contacting us.

Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

Mustang Bio (NASDAQ:MBIO) has announced that City of Hope, a cancer research and treatment center, has started enrolling patients with relapsed or treatment-resistant multiple myeloma in a CS1 chmeric antigen receptor (CAR) T cell therapy (MB-104) trial. As quoted in the press release: The Phase 1 clinical trial is the first autologous CAR T trial … Continued

Mustang Bio (NASDAQ:MBIO) has announced that City of Hope, a cancer research and treatment center, has started enrolling patients with relapsed or treatment-resistant multiple myeloma in a CS1 chmeric antigen receptor (CAR) T cell therapy (MB-104) trial.

As quoted in the press release:

The Phase 1 clinical trial is the first autologous CAR T trial to target the CS1 protein, which is expressed by cancer cells in nearly all multiple myeloma patients. CS1 also has a low expression on normal tissues, preventing those cells from being severely damaged during treatment.

“Multiple myeloma accounts for 10% of all blood and bone marrow cancers. CS1 is a very promising target for multiple myeloma patients who currently have few viable treatment options,” said Xiuli Wang, Ph.D., City of Hope research professor in the Department of Hematology & Hematopoietic Cell Transplantation. Dr. Wang’s team developed the CS1 CAR T and tested it successfully in preclinical and translational research.

To qualify for the trial, multiple myeloma patients will need to have tried three other treatment options and experienced a relapse or found that the disease is treatment-resistant, and they must test positive for the CS1 antigen. During the trial, the patients’ T cells will be collected intravenously and reengineered in a City of Hope good manufacturing practice (GMP) facility to express CS1 CARs. The CAR T cells will then be multiplied in a lab and infused back into the patient, where they are expected to proliferate inside a patient’s body and better recognize and kill cancer cells.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “This groundbreaking CS1 CAR T trial represents an exciting development for multiple myeloma patients. We look forward to learning more about its potential to address this difficult-to-treat disease.”

Click here to read the full press release.

biotech-stocks-conference

Looking for great biotech companies?

Find new opportunities and valuable news in your free report

You might also like

Comments are closed.